Anomaly

Prediction against payer behavior is the product and could not be done with rules. The company states its engine analyzes hundreds of millions of healthcare encounters to learn payer specific rules for each provider, continuously adapting as payer behavior shifts, and predicting the exact claim line payment and associated denial reason before submission. Its own framing is the point: payer policies are unreliable, so the system infers actual behavior from claims data rather than encoding published rules.

The system predicts and surfaces rather than acts: providers receive a real time response identifying actionable claim errors so staff can correct them before submission. Three applications separate the functions cleanly, covering prediction of at risk payments, detection of emerging denial patterns, and prioritization of unresolved denials for recovery. Human billing staff remain the actor throughout, which is the appropriate design given the output feeds a claim submitted under the provider's own attestation.

The company is specific about inputs and outputs, describing analysis of thousands of parameters across billions of claims to produce claim line level payment and denial predictions, and states the engine arrives pre trained so customers get predictions from day one without data extracts. It also publishes precision figures with an unusual and welcome qualifier about recall, noted below. What is absent is model architecture, validation methodology, or any independent evaluation.

Evidence is quantified with an honesty that deserves noting. The company reports over 97 percent precision in predicting claim line denials and reasons, based on analysis of more than 100 billion dollars of billed charges, and separately states that precision is achieved for up to half of total denials, which is an explicit disclosure of recall. Publishing the recall limit alongside a precision claim is rare and materially changes how a buyer should read it: the system is highly accurate on the denials it flags and does not claim to catch them all. Later materials cite over 99 percent precision on claim line payment prediction. Distribution through a national health information network under a white labeled name is meaningful third party validation. No independent audit or customer outcome study was located.

No published PHI framework or data governance disclosure was located. The platform sits in the live claims flow across providers, clearinghouses, and payers, which is a broad and continuous data surface, and the company's model improves with aggregate claims volume, so a buyer should establish how their claims data contributes to models serving other customers.

No HIPAA or BAA commitment was located in public materials, though business associate status is structurally required for a vendor processing claims transactions on behalf of providers and payers.

No SOC 2, HITRUST, or ISO 27001 attestation was located, and no trust center was found.

No FDA pathway applies. The platform operates entirely on claims and payment data with no clinical decision surface. The regulatory environment that matters here is payer side, including the CMS interoperability and prior authorization rule reshaping electronic transaction requirements, and no public position on that was located.

No governance framework or bias evaluation was located. The relevant question is whether prediction accuracy varies by payer, geography, specialty, or line of business, since a model learned from aggregate claims will be strongest where volume is densest and a smaller provider in an underrepresented market may get materially weaker predictions than the headline precision suggests.

Integration is with the claims pipeline rather than the chart, and it is the right surface for this product: the engine operates inside providers' native workflows by integrating with payers, practice management software, and claims clearinghouses, delivering predictions before the claim leaves the building. The strongest signal is distribution through a national real time health information network, where the engine is offered to that network's customers under a white labeled name, which puts it in front of provider organizations without a direct integration project.

No hosting, tenancy, or data residency disclosure was located. The company notes the engine requires no complex setup or manual data extracts, which implies a hosted service in the transaction path, but no infrastructure terms are published.

No published pricing. Third party categorization describes an enterprise pricing model, and the dual distribution path, direct plus embedded through a health information network, likely carries different economics, neither of which is disclosed.

Coverage is defined by payer breadth rather than clinical specialty, which is the correct frame here: the company reports operating across thousands of payers, all 50 states, and all lines of business including commercial, Medicare, and Medicaid. Stated buyers span integrated delivery networks, academic and community hospitals, and large laboratory and pathology organizations, alongside payers and service companies. The platform is specialty agnostic because it models payer behavior rather than clinical content.